Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Cancer|January 23, 2015
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trialJohn D Hainsworth, Gedske Daugaard, Thierry Lesimple, et al.
Cancer Immunology, Immunotherapy : CII|April 12, 2003
Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effectsThierry Lesimple, Annick Moisan, André Carsin, et al.
Investigational New Drugs|November 13, 2012
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumorsThierry Lesimple, Julien Edeline, Timothy J Carrothers, et al.
Cancers|August 26, 2022
Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster TrialDiane Marcé, Floriane Le Vilain-Abraham, Morgiane Bridou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patientsThierry Lesimple, Eve-Marie Neidhard, Virginie Vignard, et al.
The Journal of Investigative Dermatology|October 13, 2020
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017Florence Poizeau, Sandrine Kerbrat, André Happe, et al.
Bulletin Du Cancer|January 13, 2004
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]Thierry Lesimple, Jean-Jacques Voigt, Anne Bataillard, et al.
The American Journal of Surgical Pathology|December 10, 2015
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the ScalpSebastian Costa, Michelle Byrne, Daniel Pissaloux, et al.
Bulletin Du Cancer|November 21, 2002
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]Roland Bugat, Anne Bataillard, Thierry Lesimple, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2022
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Caroline Robert, Jean-Jacques Grob, et al.
Pageof 8